Capmatinib in Japanese patients with MET exon 14 skipping–mutated or MET ‐amplified advanced NSCLC: GEOMETRY mono‐1 study

Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer

(2020) Jürgen Wolf et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of pembrolizumab for patients with both high PD-L1 expression and an MET exon 14 skipping mutation: A case report

(2019) Keisuke Baba et al.   Thoracic Cancer

Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation

(2019) Sabrina Baltschukat et al.   CLINICAL CANCER RESEARCH

Phase I dose‐escalation study of capmatinib ( INC 280) in Japanese patients with advanced solid tumors

(2019) Taito Esaki et al.   CANCER SCIENCE

Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping

(2019) Wei Jin et al.   Journal of Thoracic Oncology

Multidisciplinary consensus statement on the clinical management of patients with stage III non-small cell lung cancer

(2019) M. Majem et al.   Clinical & Translational Oncology

MET Expression in Advanced Non–Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy

(2018) Henning Reis et al.   Clinical Lung Cancer

Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer – A systematic review and meta-analysis

(2018) Huy Gia Vuong et al.   LUNG CANCER

OUP accepted manuscript

(2018)   ANNALS OF ONCOLOGY

PD-L1 Expression, Tumor Mutational Burden, and Response to Immunotherapy in Patients with MET exon 14 Altered Lung Cancers

(2018) J K Sabari et al.   ANNALS OF ONCOLOGY

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

The Role of Targeted Agents and Immunotherapy in Older Patients with Non-small Cell Lung Cancer

(2018) Fabio Gomes et al.   DRUGS & AGING

Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor–Dysregulated Non–Small-Cell Lung Cancer

(2018) Yi-Long Wu et al.   JOURNAL OF CLINICAL ONCOLOGY

Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody

(2018) Jianqun Kou et al.   Journal of Translational Medicine

Treatment of older patients with advanced non-small cell lung cancer: A challenge

(2018) Lore Decoster et al.   Journal of Geriatric Oncology

Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping

(2017) Sai-Hong Ignatius Ou et al.   Journal of Thoracic Oncology

Mutation of MET Y1230 as an Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping

(2017) Alexa B. Schrock et al.   Journal of Thoracic Oncology

Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project

(2017) Lukas Bubendorf et al.   LUNG CANCER

MET overexpression and gene amplification: prevalence, clinico-pathological characteristics and prognostic significance in a large cohort of patients with surgically resected NSCLC

(2017) William Sterlacci et al.   VIRCHOWS ARCHIV

Changing the Therapeutic Landscape in Non-small Cell Lung Cancers: the Evolution of Comprehensive Molecular Profiling Improves Access to Therapy

(2017) Joshua K. Sabari et al.   Current Oncology Reports

Gene aberrations for precision medicine against lung adenocarcinoma

(2016) Motonobu Saito et al.   CANCER SCIENCE

MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life

(2016) A. Drilon   CLINICAL CANCER RESEARCH

MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis

(2016) J. H. Tong et al.   CLINICAL CANCER RESEARCH

MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression

(2016) Mark M. Awad et al.   JOURNAL OF CLINICAL ONCOLOGY

Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations

(2016) Alexa B. Schrock et al.   Journal of Thoracic Oncology

MET Exon 14 Skipping in Non-Small Cell Lung Cancer

(2016) Rebecca S. Heist et al.   ONCOLOGIST

Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers

(2015) Deepa Rangachari et al.   LUNG CANCER

Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping

(2015) P. K. Paik et al.   Cancer Discovery

Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors

(2015) G. M. Frampton et al.   Cancer Discovery

Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches

(2015) Meghan Shea et al.   Therapeutic Advances in Respiratory Disease

Comprehensive molecular profiling of lung adenocarcinoma

(2014) Eric A. Collisson et al.   NATURE

A Novel Kinase Inhibitor, INCB28060, Blocks c-MET-Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3

(2011) X. Liu et al.   CLINICAL CANCER RESEARCH

c-MET/Phospho-MET Protein Expression and MET Gene Copy Number in Non-small Cell Lung Carcinomas

(2011) Koji Tsuta et al.   Journal of Thoracic Oncology

Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung Cancers

(2010) Ryoichi Onozato et al.   Journal of Thoracic Oncology

High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer

(2010) Heounjeong Go et al.   Journal of Thoracic Oncology

IncreasedMETGene Copy Number Negatively Affects Survival of Surgically Resected Non–Small-Cell Lung Cancer Patients

(2009) Federico Cappuzzo et al.   JOURNAL OF CLINICAL ONCOLOGY

Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer

(2008) Katsuhiro Okuda et al.   CANCER SCIENCE